494 related articles for article (PubMed ID: 31088823)
1. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands.
de Blok CJM; Wiepjes CM; Nota NM; van Engelen K; Adank MA; Dreijerink KMA; Barbé E; Konings IRHM; den Heijer M
BMJ; 2019 May; 365():l1652. PubMed ID: 31088823
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment.
de Nie I; de Blok CJM; van der Sluis TM; Barbé E; Pigot GLS; Wiepjes CM; Nota NM; van Mello NM; Valkenburg NE; Huirne J; Gooren LJG; van Moorselaar RJA; Dreijerink KMA; den Heijer M
J Clin Endocrinol Metab; 2020 Sep; 105(9):e3293-9. PubMed ID: 32594155
[TBL] [Abstract][Full Text] [Related]
3. Frequency and outcomes of benign breast biopsies in trans women: A nationwide cohort study.
de Blok CJ; Dijkman BA; Wiepjes CM; Konings IR; Dreijerink KM; Barbé E; den Heijer M
Breast; 2021 Jun; 57():118-122. PubMed ID: 33831630
[TBL] [Abstract][Full Text] [Related]
4. Sustained Breast Development and Breast Anthropometric Changes in 3 Years of Gender-Affirming Hormone Treatment.
de Blok CJM; Dijkman BAM; Wiepjes CM; Staphorsius AS; Timmermans FW; Smit JM; Dreijerink KMA; den Heijer M
J Clin Endocrinol Metab; 2021 Jan; 106(2):e782-e790. PubMed ID: 33206172
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment.
Gooren LJ; van Trotsenburg MA; Giltay EJ; van Diest PJ
J Sex Med; 2013 Dec; 10(12):3129-34. PubMed ID: 24010586
[TBL] [Abstract][Full Text] [Related]
6. [Hormone treatment of transgender people: Long-term health effects and safety].
de Blok CJM; Wiepjes CM; Nota NM; den Heijer M
Ned Tijdschr Geneeskd; 2020 Jul; 164():. PubMed ID: 32757514
[TBL] [Abstract][Full Text] [Related]
7. Oestrogen and anti-androgen therapy for transgender women.
Tangpricha V; den Heijer M
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):291-300. PubMed ID: 27916515
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Gender-Affirming Hormone Therapy and Cognitive Functioning in Older Transgender Women Compared With Cisgender Women and Men.
van Heesewijk JO; Dreijerink KMA; Wiepjes CM; Kok AAL; van Schoor NM; Huisman M; den Heijer M; Kreukels BPC
J Sex Med; 2021 Aug; 18(8):1434-1443. PubMed ID: 34247950
[TBL] [Abstract][Full Text] [Related]
9. Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria.
de Blok CJ; Wiepjes CM; van Velzen DM; Staphorsius AS; Nota NM; Gooren LJ; Kreukels BP; den Heijer M
Lancet Diabetes Endocrinol; 2021 Oct; 9(10):663-670. PubMed ID: 34481559
[TBL] [Abstract][Full Text] [Related]
10. Gender-Affirming Hormone Therapy Modifies the CpG Methylation Pattern of the ESR1 Gene Promoter After Six Months of Treatment in Transmen.
Fernández R; Ramírez K; Gómez-Gil E; Cortés-Cortés J; Mora M; Aranda G; Zayas ED; Esteva I; Almaraz MC; Guillamon A; Pásaro E
J Sex Med; 2020 Sep; 17(9):1795-1806. PubMed ID: 32636163
[TBL] [Abstract][Full Text] [Related]
11. The Amsterdam Cohort of Gender Dysphoria Study (1972-2015): Trends in Prevalence, Treatment, and Regrets.
Wiepjes CM; Nota NM; de Blok CJM; Klaver M; de Vries ALC; Wensing-Kruger SA; de Jongh RT; Bouman MB; Steensma TD; Cohen-Kettenis P; Gooren LJG; Kreukels BPC; den Heijer M
J Sex Med; 2018 Apr; 15(4):582-590. PubMed ID: 29463477
[TBL] [Abstract][Full Text] [Related]
12. Breast and cervical cancer screenings across gender identity: results from the Behavioral Risk Factor Surveillance System before and during the COVID-19 pandemic.
Berzansky I; Reynolds CA; Charlton BM
Cancer Causes Control; 2024 May; 35(5):865-872. PubMed ID: 38280155
[TBL] [Abstract][Full Text] [Related]
13. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study.
Getahun D; Nash R; Flanders WD; Baird TC; Becerra-Culqui TA; Cromwell L; Hunkeler E; Lash TL; Millman A; Quinn VP; Robinson B; Roblin D; Silverberg MJ; Safer J; Slovis J; Tangpricha V; Goodman M
Ann Intern Med; 2018 Aug; 169(4):205-213. PubMed ID: 29987313
[TBL] [Abstract][Full Text] [Related]
14. Difficulties of gender affirming treatment in trans women with BRCA1+ mutation: A case report.
Piñar-Gutiérrez A; Dueñas Disotuar S; de Lara-Rodríguez I; Amuedo-Domínguez S; González-Cejudo C; Tejero-Delgado J; Mangas-Cruz MÁ
Endocrinol Diabetes Nutr (Engl Ed); 2024 Mar; 71(3):144-148. PubMed ID: 38555112
[TBL] [Abstract][Full Text] [Related]
15. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.
Wierckx K; Van Caenegem E; Schreiner T; Haraldsen I; Fisher AD; Toye K; Kaufman JM; T'Sjoen G
J Sex Med; 2014 Aug; 11(8):1999-2011. PubMed ID: 24828032
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review.
Streed CG; Harfouch O; Marvel F; Blumenthal RS; Martin SS; Mukherjee M
Ann Intern Med; 2017 Aug; 167(4):256-267. PubMed ID: 28738421
[TBL] [Abstract][Full Text] [Related]
17. The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment.
Nota NM; Wiepjes CM; de Blok CJM; Gooren LJG; Peerdeman SM; Kreukels BPC; den Heijer M
Brain; 2018 Jul; 141(7):2047-2054. PubMed ID: 29688280
[TBL] [Abstract][Full Text] [Related]
18. Effects of Gender-Affirming Hormones on Lipid, Metabolic, and Cardiac Surrogate Blood Markers in Transgender Persons.
Defreyne J; Van de Bruaene LDL; Rietzschel E; Van Schuylenbergh J; T'Sjoen GGR
Clin Chem; 2019 Jan; 65(1):119-134. PubMed ID: 30602477
[TBL] [Abstract][Full Text] [Related]
19. A Comparison of Trans Women, Trans Men, Genderqueer Individuals, and Cisgender Brothers and Sisters on the Bem Sex-Role Inventory: Ratings by Self and Siblings.
Factor RJ; Rothblum ED
J Homosex; 2017; 64(13):1872-1889. PubMed ID: 27983897
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
